Alzheimer's disease is characterized by the presence of senile plaques formed from beta amyloid (A.beta.), and neurofibrillary tangles (NTFs) formed from paired helical filaments consisting of hyperphosphorylated tau. A number of studies have shown that the NTFs correlate better with the duration and severity of Alzheimer's disease than senile plaques. However, a criticism of the primary etiological role of NTFs in Alzheimer's disease is the absence of variants of kinases or phosphatases associated with Alzheimer's disease. Acid phosphatase, a product of the ACP 1 gene, is a ubiquitous low molecular weight protein tyrosine phosphatase. A common allele, ACP 1*A, is associated with a lower activity of acid phosphatase. It is due to an Arg 105 Gln substitution of the ACP1 locus and detected as a Taq I polymorphism. We report a significant association of the low activity 2 allele with sporadic early onset Alzheimer's disease (EOAD). These findings support the possibility that other variants of kinase and genes may be associated with sporadic Alzheimer's disease.

City of Hope

Association between the acid phosphatase (ACP1) gene and Alzheimer's disease

The present invention provides a method of inhibiting .beta.-amyloid toxicity in brain cells. The method includes administering to the cells an amount of an alkaline phosphatase inhibitor which is pharmacologically effective to reduce degeneration in the cells. Methods of treatment of peripheral neuropathy are also provided using acid or alkaline phosphatase inhibitors.

Cortex Pharmaceuticals, Inc.

Alkaline and acid phosphatase inhibitors in treatment of neurological disorders

A method of regulating phosphorylation of proteins involved in controlling processing or function of key proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques associated with Alzheimer disease comprising introducing an effective amount of a kinase modulator or phosphatase modulator, the modulator capable of increasing or decreasing the rate of proteolytic processing, or modulating the function, of said key proteins.

The Rockefeller University

Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation

The present invention concerns the antidiabetic-activity of compounds type A, namely of 8-.beta.-D-glucosylgenistein, which is not toxic to eukaryotic cells and has demonstrated to produce complete normalization of fasting hyperglycaemia, to reduce excessive postprandial glucose excursion, to increase glucose-induced insulin secretion and insulin sensitivity. An alternative synthesis for this molecular entity and its binding ability to .beta.-amyloid oligomers is also included in the present invention, which also comprises Genista tenera ethyl acetate extract for use as antihyperglycaemic, agent i.e. for lowering blood glucose levels in mammals that are pre-diabetic or have type 2 or type 1 diabetes. The inhibitory activity of .alpha.-glucosidase by Genista tenera ethyl acetate and butanol extracts and that of glucose-6-phosphatase by these two extracts and the diethyl ether plant extract is also part of the present invention.

FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA

C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents

amyloidosis/phosphatase

Association between the acid phosphatase (ACP1) gene and Alzheimer's disease

Alkaline and acid phosphatase inhibitors in treatment of neurological disorders

Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation

C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus